局限期小细胞肺癌合并间质性肺异常放化疗研究
该回顾性研究纳入2009至2016年149例一线治疗的局限期小细胞肺癌患者,发现间质性肺异常(ILAs)者放射性肺炎发生率显著更高(64% vs 10%,P<0.001),且ILAs为独立不良预后因素;但合并ILAs者接受放化疗仍有长期生存可能(2年36%、5年26%)。
要点
- 合并ILAs的LS-SCLC患者放射性肺炎发生率显著高于无ILAs者(64% vs 10%)。
- ILAs是多因素分析中放射性肺炎发生及不良预后的独立因素。
- 合并ILAs者放化疗后2年、5年生存率分别为36%、26%,仍有长期生存可能。
核心结论
- ILAs是接受放化疗的LS-SCLC患者发生放射性肺炎的预测因素,也是独立的负性预后因素。
- 合并ILAs的LS-SCLC患者接受放化疗既有长期生存可能,也存在放射性肺炎风险。
主要发现
- 单因素分析中,合并ILAs者放射性肺炎发生率高于无ILAs者(64% vs 10%,P<0.001)。
- 多因素分析证实ILAs与放射性肺炎发生显著相关。
- 单因素分析中,合并ILAs者总生存差于无ILAs者(中位18.9 vs 67.9个月,P=0.0338)。
- 多因素分析显示ILAs是显著的独立负性预后因素。
- 合并ILAs者放化疗后2年、5年生存率分别为36%、26%;单纯化疗者分别为8%、0%。
临床怎么用
- 对LS-SCLC患者放化疗前应关注ILAs,以识别放射性肺炎高风险人群。
- 合并ILAs者不应仅因风险而放弃放化疗,因其仍可能获得长期生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with lung cancer and interstitial lung disease treated with radiotherapy are at risk of developing radiation pneumonitis. However, the association between interstitial lung abnormalities (ILAs) and radiation pneumonitis in patients with limited-stage small-cell lung cancer (LS-SCLC) remains unclear. Furthermore, the prognosis is uncertain for patients with SCLC and ILAs treated with chemoradiotherapy. We investigated the impact of ILAs on radiation pneumonitis and assessed the prognosis of patients with LS-SCLC and ILAs treated with chemoradiotherapy. METHODS: We retrospectively reviewed the medical records of 149 patients with LS-SCLC who received first-line treatment between January 2009 and December 2016. RESULTS: In the univariate analysis, the patients with ILAs showed a higher incidence rate of radiation pneumonitis compared with those without ILAs (64% vs. 10%, P < 0.001). Multivariate analysis confirmed that ILAs were significantly associated with the incidence of radiation pneumonitis. In the univariate analysis, patients with ILAs showed poorer overall survival than those without ILAs (median, 18.9 vs. 67.9 months, P = 0.0338). Multivariate analysis showed that ILAs were a significant independent negative prognostic factor. However, the 2-year and 5-year survival rates for the patients with ILAs treated with chemoradiotherapy were 36% and 26%, respectively, and 8% and 0%, respectively, for those treated with chemotherapy alone. CONCLUSIONS: ILAs were found to be a predictive factor for radiation pneumonitis in patients with LS-SCLC treated with chemoradiotherapy. Patients with LS-SCLC and ILAs who were treated with chemoradiotherapy had both the possibility of long-term survival and risk of radiation pneumonitis.
引用
- Kobayashi H, Wakuda K, Naito T, et al. Chemoradiotherapy for limited-stage small-cell lung cancer and interstitial lung abnormalities. Radiat Oncol. 2021. PMID: 33731123. doi:10.1186/s13014-021-01780-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。